Glucose Monitor Helps Type 2 Diabetics Control Blood Sugar

Millions of people with Type 2 diabetes who don't take insulin could soon get access to a device that's already transforming care for others.

New research shows that Dexcom's G7 continuous glucose monitor helped people with Type 2 diabetes dramatically improve their blood sugar control over six months. Participants using the device saw their HbA1c levels drop by 0.9% compared to those using traditional finger-prick testing.

Even better, CGM users spent five additional hours each day in the healthy blood sugar range of 70 to 180 mg/dL. That's five more hours when their bodies aren't being damaged by high glucose levels.

The study tracked participants for 26 weeks and found results that Dexcom calls both statistically and clinically significant. The company presented the findings at the American Diabetes Association scientific sessions this month.

Right now, continuous glucose monitors are primarily available to people with Type 1 diabetes or Type 2 patients who take insulin. But this study focused on a much larger group: Type 2 diabetics managing their condition without insulin.

The timing matters because Medicare is reviewing whether to cover CGM devices for this broader population. Dexcom expects a decision by the end of this year.

The Ripple Effect

If Medicare approves coverage, the impact could reach millions of Americans living with Type 2 diabetes. Continuous glucose monitors eliminate the need for painful finger sticks throughout the day and provide real-time feedback that helps people understand how food, activity, and stress affect their blood sugar.

The device works by wearing a small sensor on the skin that continuously tracks glucose levels and sends data to a smartphone app. Users can see patterns and trends that finger-prick tests miss entirely.

The technology also removes much of the guesswork from diabetes management. Instead of wondering whether that meal spiked their blood sugar, users know immediately and can adjust their choices.

Dexcom is so confident in the technology's broader applications that it recently announced plans to acquire Nutrisense, an app that helps users analyze glucose data and make lifestyle changes. The move signals the company's belief that continuous monitoring has value beyond traditional diabetes care.

A full peer-reviewed publication of the study results is currently in the works, which will allow other researchers and clinicians to review the complete findings.

For now, the data represents genuine progress toward making powerful health technology available to more people who need it.